[go: up one dir, main page]

WO2023035571A1 - Procédés de synthèse de l'esaxérénone et de son intermédiaire - Google Patents

Procédés de synthèse de l'esaxérénone et de son intermédiaire Download PDF

Info

Publication number
WO2023035571A1
WO2023035571A1 PCT/CN2022/080532 CN2022080532W WO2023035571A1 WO 2023035571 A1 WO2023035571 A1 WO 2023035571A1 CN 2022080532 W CN2022080532 W CN 2022080532W WO 2023035571 A1 WO2023035571 A1 WO 2023035571A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
compound formula
limited
synthetic method
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/080532
Other languages
English (en)
Chinese (zh)
Inventor
阮晶
张鑫鑫
严恭超
阮晓娜
张薇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Original Assignee
Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Dingya Pharmaceutical Chemicals Co Ltd filed Critical Shanghai Dingya Pharmaceutical Chemicals Co Ltd
Publication of WO2023035571A1 publication Critical patent/WO2023035571A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to the field of organic synthesis, in particular, to a synthetic method for an eschacillinone intermediate, and in addition to a synthetic method for eschacillinone.
  • ethacillinone is (5P)-1-(2-hydroxyethyl)-N-[4-(methylsulfonyl)phenyl]-4-methyl-5-[2-(trifluoromethyl ) phenyl]-1H-pyrrole-3-carboxamide, the structural formula is as follows:
  • MR mineralocorticoid receptor
  • the preparation method of key intermediate IV is also reported, such as patent documents CN102186817A and WO2021078135A1.
  • the preparation methods of key intermediate IV disclosed in the above patent documents are all prepared by Suzuki coupling reaction, and the palladium catalyst used in this reaction is expensive. The cost is high, and ligands need to be added, which is not conducive to purification and industrial production.
  • the cyclization step of this route uses hydrogen chloride gas as the reaction material, which is highly corrosive, and the palladium metal catalyst used in the chlorine group removal step is expensive and costly, which is not conducive to industrial scale-up production.
  • the present invention provides a synthetic method of an eschacillinone intermediate, which has the advantages of high yield, simple aftertreatment, low cost, and ease of industrialization, while making the product meet the purity required for registration of raw materials.
  • One of purpose of the present invention is to provide a kind of synthetic method of new eschacillinone intermediate, to solve the existing synthetic method of eschacillinone intermediate that preparation yield is low, cost is high, post-processing is complicated and inconvenient Conducive to the problem of industrialized production.
  • the first aspect of the present invention provides a kind of synthetic method of new oxacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:
  • step (1) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;
  • step (3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form the pyrrole ring compound formula IV in the presence of a base and a metal catalyst;
  • the process route is as follows:
  • the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2
  • the molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5 ⁇ 1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1 ⁇ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.
  • the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ;
  • the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.;
  • Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.
  • the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.
  • the second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.
  • the third aspect of the present invention also provides a synthetic method of a new oxacillinone intermediate compound formula V, the synthetic method comprising the following steps: the above-mentioned pyrrole ring compound formula IV in a solvent, under the condition of the presence of a base, and Reaction preparation obtains compound formula V;
  • the structural formula of intermediate compound formula V is as follows:
  • the X is halogen, and the A is hydroxyl or halogen.
  • the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent;
  • the alcohol solvent includes but not limited to ethanol;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane
  • the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide;
  • the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine,
  • the fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.
  • the fifth aspect of the present invention also provides a kind of synthetic method of new ethacillinone, adopts following technical scheme:
  • the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • PyBop Benzotriazol-1-yl-oxytripyrrolidinyl
  • DIPEA N,N-diisopropylethylamine
  • the sixth aspect of the present invention also provides a second new preparation method of ethacillinone, which adopts the following technical scheme: the above-mentioned ethacillinone intermediate compound formula V is reacted with a suitable acylating reagent to obtain the acid chloride compound formula VII, The acid chloride compound formula VII is acylated with 4-methanesulfonylanilide to obtain compound VI, wherein the structural formula of the acid chloride compound formula VII is as follows:
  • the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine;
  • the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides
  • Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.
  • the seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.
  • the existing synthetic methods of oxacillinone intermediates have the problems of low preparation yield, high cost, complicated post-processing and unfavorable industrial production.
  • the application provides a kind of synthetic method of new eschacillinone intermediate compound formula IV, and this synthetic method comprises the following steps:
  • step (1) The amide compound formula II obtained in step (1) is prepared through a dehydration reaction in the presence of a dehydrating agent and an acid-binding agent to obtain an isonitrile compound formula III;
  • step (3) The isonitrile compound formula III obtained in step (2) is cyclized with ethyl 2-butynoate to form pyrrole ring compound IV in the presence of a base and a metal catalyst;
  • the process route is as follows:
  • the inert solvent described in step (1) includes but not limited to one or more of the group consisting of halogenated hydrocarbons, benzene, toluene, ether, xylene, nitrobenzene, and acetonitrile; One or more of imidazole, pyridine, tetrabutylammonium fluoride, 2,6-lutidine, potassium carbonate, N,N-diisopropylethylamine, sodium carbonate, and triethylamine; 2
  • the molar ratio of -(trifluoromethyl)phenylacetic acid to base is 1:0.5 ⁇ 1; the molar ratio of 2-(trifluoromethyl)phenylacetic acid to ethyl chloroformate or isobutyl chloroformate is 1:1 ⁇ 1.5; the reaction temperature is 0° C. to room temperature; the reaction time is 12 hours to 36 hours.
  • the dehydrating agent described in step (2) is one or more of P 2 O 5 , PCl 3 , SOCl 2 , COCl 2 , ArSO 2 Cl, POCl 3 ;
  • the acid-binding agent is an organic base Or inorganic base, described inorganic base is sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, potassium tert-butoxide etc.;
  • Described organic base is triethylamine, diisopropylamine; Described solvent selects halogenated alkanes, two Chloromethane, dichloroethane.
  • the base in step (3) is Pr 3 N, pyridine, DBU, TEEDA; the metal catalyst is Cu 2 O, CuCl, CuI, CuBr, Cu(OMe) 2 , copper powder.
  • the raw material 2-(trifluoromethyl)phenylacetic acid (compound formula I) can be purchased.
  • the second aspect of the present invention also provides the esacillinone intermediate compound formula IV, which is prepared by the above synthesis process.
  • the third aspect of the present invention also provides a kind of synthetic method of new oxacillinone intermediate compound formula V, and this synthetic method is as follows:
  • the specific synthetic method comprises the following steps: the pyrrole ring compound formula IV obtained by the above synthesis is mixed with The compound formula V is prepared by reaction, wherein said X is halogen, and said A is hydroxyl or halogen.
  • the solvent is an alcohol solvent, a halogenated hydrocarbon solvent, an aromatic hydrocarbon solvent, an ether solvent or an amide solvent;
  • the alcohol solvent includes but not limited to ethanol;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane
  • the amide solvent includes but not limited to N,N-dimethylacetamide, N,N-dimethylformamide;
  • the alkali is sodium hydroxide, potassium hydroxide, lithium hydroxide, tert-butanol Sodium, potassium tert-butoxide, cesium carbonate, sodium hydride, potassium carbonate, sodium carbonate, 4-dimethylaminopyridine, N,N-diisopropylethylamine,
  • the fourth aspect of the present invention also provides the esacillinone intermediate compound formula V, which is prepared by the aforementioned synthesis process.
  • the fifth aspect of the present invention also provides a new synthetic method of ixacillinone, the preparation method is as follows:
  • the specific synthesis method includes the following steps: condensing the above-mentioned oxacillinone intermediate compound formula V and 4-methanesulfonylaniline under the action of a condensing agent to obtain oxacillinone (compound formula VI).
  • the condensing agent is 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBT), and the solvent is dry N,N-dimethylformamide (DMF), in addition to adding a certain amount of alkali, commonly used alkali is N,N-diisopropylethylamine (DIPEA), triethylamine, pyridine, hexafluorophosphoric acid Benzotriazol-1-yl-oxytripyrrolidinyl (PyBop), preferably N,N-diisopropylethylamine (DIPEA).
  • DIPEA N,N-diisopropylethylamine
  • PyBop Benzotriazol-1-yl-oxytripyrrolidinyl
  • DIPEA N,N-diisopropylethylamine
  • the sixth aspect of the present invention also provides the second new synthetic method of ixacillinone, the synthetic method is as follows:
  • the specific preparation method includes the following steps: react the above-mentioned ethacillinone intermediate compound V with a suitable acylating agent to obtain the acyl chloride compound VII, and then acylate the acyl chloride compound VII with 4-methylsulfonylanilide to obtain the compound VI.
  • the acylating agent is oxalyl chloride, and the acylating reaction is preferably carried out in the presence of a base and a solvent, and the base is an organic base or an inorganic base, including but not limited to triethylamine, N , N-diisopropylethylamine;
  • the solvent is halogenated hydrocarbon solvent, aromatic hydrocarbon solvent, ether solvent or amide solvent;
  • the halogenated hydrocarbon solvent includes but not limited to dichloromethane or chloroform ;
  • the aromatic hydrocarbon solvents include but not limited to toluene, benzene, xylene or nitrobenzene;
  • the ether solvents include but not limited to tetrahydrofuran, 1,4-dioxane or the amides
  • Solvents include, but are not limited to, N,N-dimethylacetamide, N,N-dimethylformamide.
  • the seventh aspect of the present invention also provides eschacillinone, which is prepared by any one of the aforementioned synthesis processes.
  • reaction solution was cooled to room temperature, and the pH was adjusted to 5-6 with 2N hydrochloric acid, and the layers were allowed to stand.
  • the aqueous phase was extracted twice with dichloromethane, and the organic phases were combined. , dried and concentrated to obtain 14.7 g of 1-(2-hydroxyethyl)4-methyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid with a yield of 94%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un nouveau procédé de synthèse d'un intermédiaire de l'ésaxérénone. Le procédé comprend les étapes suivantes consistant à : (1) Faire réagir de l'acide 2-(trifluorométhyl)phénylacétique en tant que matière première avec du chloroformiate d'éthyle ou du chloroformiate d'isobutyle dans un solvant inerte en présence d'un alcali pour produire un anhydride mixte, puis le faire réagir avec de l'ammoniac pour obtenir un composé amide correspondant de formule II ; (2) soumettre le composé amide de formule II obtenu à l'étape (1) à une réaction de déshydratation en présence d'un agent déshydratant et d'un agent de liaison à l'acide pour obtenir un composé isocyanure de formule III ; et (3) soumettre le composé isocyanure de formule III obtenu à l'étape (2) à une réaction de cyclisation avec du 2-butynonate d'éthyle en présence d'un alcali et d'un catalyseur métallique pour former un composé cyclique de pyrrole de formule IV ; et l'équation de réaction est représentée ci-dessous : Par rapport à l'état de la technique, la solution technique selon la présente invention a les avantages d'un rendement élevé, d'un post-traitement simple, de coûts faibles et d'une industrialisation facile, etc.
PCT/CN2022/080532 2021-09-10 2022-03-13 Procédés de synthèse de l'esaxérénone et de son intermédiaire Ceased WO2023035571A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111063792.3 2021-09-10
CN202111063792.3A CN115784961A (zh) 2021-09-10 2021-09-10 埃沙西林酮及其中间体的合成方法

Publications (1)

Publication Number Publication Date
WO2023035571A1 true WO2023035571A1 (fr) 2023-03-16

Family

ID=85473617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/080532 Ceased WO2023035571A1 (fr) 2021-09-10 2022-03-13 Procédés de synthèse de l'esaxérénone et de son intermédiaire

Country Status (2)

Country Link
CN (1) CN115784961A (fr)
WO (1) WO2023035571A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510400A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种6-溴-2-氯-3-硝基吡啶的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119306645A (zh) * 2023-07-12 2025-01-14 广东东阳光药业股份有限公司 制备吡咯酰胺化合物的方法及其中间体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1844020A1 (fr) * 2005-01-10 2007-10-17 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques
CN101679243A (zh) * 2007-04-09 2010-03-24 第一三共株式会社 吡咯衍生物的阻转异构体
WO2010098286A1 (fr) * 2009-02-25 2010-09-02 第一三共株式会社 Préparation pharmaceutique contenant un antagoniste des récepteurs de minéralocorticoïdes
CN102186817A (zh) * 2008-10-08 2011-09-14 埃克塞利希斯股份有限公司 (羟烷基)吡咯衍生物的阻转异构体
CN105164105A (zh) * 2013-04-10 2015-12-16 第一三共株式会社 吡咯衍生物的结晶及其制备方法
CN105473552A (zh) * 2013-08-27 2016-04-06 第一三共株式会社 用于产生吡咯衍生物及其中间体的方法
CN112707854A (zh) * 2019-10-25 2021-04-27 广东东阳光药业有限公司 吡咯酰胺类化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102078528B1 (ko) * 2018-04-18 2020-02-19 성균관대학교산학협력단 신규한 hdac6 억제제를 이용한 치매 또는 인지장애 예방 또는 치료용 약학적 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1844020A1 (fr) * 2005-01-10 2007-10-17 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques
CN101679243A (zh) * 2007-04-09 2010-03-24 第一三共株式会社 吡咯衍生物的阻转异构体
CN102186817A (zh) * 2008-10-08 2011-09-14 埃克塞利希斯股份有限公司 (羟烷基)吡咯衍生物的阻转异构体
WO2010098286A1 (fr) * 2009-02-25 2010-09-02 第一三共株式会社 Préparation pharmaceutique contenant un antagoniste des récepteurs de minéralocorticoïdes
CN105164105A (zh) * 2013-04-10 2015-12-16 第一三共株式会社 吡咯衍生物的结晶及其制备方法
CN105473552A (zh) * 2013-08-27 2016-04-06 第一三共株式会社 用于产生吡咯衍生物及其中间体的方法
CN112707854A (zh) * 2019-10-25 2021-04-27 广东东阳光药业有限公司 吡咯酰胺类化合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU YUXI, DAI HONGXING, DU YUCHENG, DENG JIGUANG, ZHANG LEI, ZHAO ZHENXUAN, AU CHAK TONG: "Controlled preparation and high catalytic performance of three-dimensionally ordered macroporous LaMnO3 with nanovoid skeletons for the combustion of toluene", JOURNAL OF CATALYSIS, ACADEMIC PRESS, DULUTH, MN., US, vol. 287, 1 March 2012 (2012-03-01), US , pages 149 - 160, XP093045756, ISSN: 0021-9517, DOI: 10.1016/j.jcat.2011.12.015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510400A (zh) * 2023-11-29 2024-02-06 山西永津集团有限公司 一种6-溴-2-氯-3-硝基吡啶的制备方法

Also Published As

Publication number Publication date
CN115784961A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
EP3189053B1 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
CN102812020B (zh) 用于制备四唑甲磺酸盐的方法及其使用的新化合物
KR101472686B1 (ko) 벤즈이미다졸 유도체의 제조방법
US10927095B2 (en) Processes for the preparation of Niraparib and intermediates thereof
CN112592344B (zh) 一种吲哚并[2,3-b]吲哚类衍生物及其合成方法
WO2023035571A1 (fr) Procédés de synthèse de l'esaxérénone et de son intermédiaire
CN109988077A (zh) 一种阿帕鲁胺的合成方法及中间体
CN114805308A (zh) 一种合成氨基嘧啶类fak抑制剂化合物的方法
WO2018153380A1 (fr) Préparation de velpatasvir et de son dérivé
CN106699595A (zh) 一种拉科酰胺制备方法
WO2014067237A1 (fr) Procédé de préparation de telmisartan et son intermédiaire
CN112047879A (zh) 一种铜催化选择性合成卤代芳胺的方法
CN115557823B (zh) 一种合成酰胺类化合物的方法
CN112028827A (zh) 一种奈他地尔关键中间体的制备方法
CN112574087B (zh) 一种3-氨基吡咯烷盐酸盐的合成方法
JP2018516949A (ja) エンザルタミドを調製するための新規な方法
CN113336703B (zh) 1,3,4,5-四取代1h-吡唑衍生物的合成
CN113968815B (zh) 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
CN104230885A (zh) 伊马替尼的制备方法
JP2008531642A (ja) 薬学活性化合物イルベサルタンおよびその合成中間体を得る方法
CN109879805B (zh) 阿帕替尼的制备方法
CN114920655A (zh) 一种2-氟-3-三氟甲基苯胺的制备方法
CN106588765A (zh) 一种氮氧化物c2‑位羟基化的方法
CN113999175B (zh) 可见光催化磺酰基取代异喹啉-1,3（2h，4h）-二酮的合成方法
CN104262338A (zh) 一种阿哌沙班及其中间体的合成方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22866049

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22866049

Country of ref document: EP

Kind code of ref document: A1